enGene Therapeutics
ENGN
60 hedge funds and large institutions have $86.5M invested in enGene Therapeutics in 2026 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 23 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 16
9% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 23
3% less funds holding
Funds holding: 62 → 60 (-2)
9.3% less ownership
Funds ownership: 83.95% → 74.64% (-9.3%)
52% less capital inflows, than outflows
Capital inflows: $77.8M | Capital outflows: $163M
68% less call options, than puts
Call options by funds: $246K | Put options by funds: $770K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$27.2M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$10.9M |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$8.04M |
| 4 |
ACA
Acorn Capital Advisors
New York
|
+$5.18M |
| 5 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
+$4.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$32.5M |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
-$30.1M |
| 3 |
Deep Track Capital
Greenwich,
Connecticut
|
-$29.8M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
-$16.7M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$12.6M |
ENGN Hedge Fund Activity: Q2 2026 in Review
60 of the 8,353 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics (ENGN) for Q2 2026, worth a combined $86.5M — down 77% from $383M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ENGN and 21 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 15 added.
The largest buyer was BML Capital Management, opening a new position worth an estimated $27.2M. The largest seller was VR Adviser, exiting entirely with an estimated $32.5M sold.
- 60 institutional investors held enGene Therapeutics (ENGN) as of Q2 2026, down from 62 in Q1 2026.
- Funds reported $86.5M of enGene Therapeutics stock for Q2 2026, down 77% quarter-over-quarter.
- 21 funds opened new enGene Therapeutics positions in Q2 2026 and 23 closed out, a net change of -2 holders.
- The largest enGene Therapeutics buyer in Q2 2026 was BML Capital Management, an estimated $27.2M added.
- The largest enGene Therapeutics seller in Q2 2026 was VR Adviser, an estimated $32.5M sold.
Based on aggregated 13F filings for Q2 2026.